Clinical value of plasma copeptin in acute exacerbation of chronic obstructive pulmonary disease_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

 XU Chunhua , CHI Chuanzhen , YUAN Qi , WANG Wei , WANG Yuchao , ZHANG Qian

Endoscopic Center of Nanjing Chest Hospital, Nanjing, Jiangsu 210029, P.R.China;

Corresponding author：

XU Chunhua, Email: xuchunhua_nj@163.com

Keywords：

Chronic obstructive pulmonary disease; Acute exacerbation; Copeptin

DOI：

10.7507/1671-6205.201612029

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the clinical value of plasma copeptin in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods Ninety patients with AECOPD admitted between October 2013 and November 2015 were recruited as an AECOPD group, and 40 healthy subjects underwent physical examination simultaneously were recruited as a control group. According to patient history and severity, the AECOPD patients were divided into 3 groups: grade Ⅰ group (25 cases), grade Ⅱ group (45 cases) and grade Ⅲ group (20 cases). Plasma copeptin level was measured by enzyme-linked immunosorbent assay (ELISA). The changes of copeptin, the total counts of white blood cells (WBC), and C-reactive protein (CRP) of the AECOPD patients were compared before and after treatment. Then the correlations between plasma levels of copeptin and severity of AECOPD were evaluated. Results The plasma level of copeptin in the AECOPD group was higher than that in the control group [(16.4±5.2) pmol/L vs. (5.7±2.8) pmol/L, P<0.05), and gradually increased with the severity of AECOPD. For the AECOPD patients both before and after treatment, the copeptin concentrations were positive correlated with the plasma CRP concentrations and the total counts of WBC in blood (both P<0.05). Conclusions The plasma levels of copeptin gradually increase with the severity of AECOPD. The changes of plasma copeptin may be as an indicator for the severity of AECOPD.

Citation： XU Chunhua, CHI Chuanzhen, YUAN Qi, WANG Wei, WANG Yuchao, ZHANG Qian. Clinical value of plasma copeptin in acute exacerbation of chronic obstructive pulmonary disease. Chinese Journal of Respiratory and Critical Care Medicine, 2017, 16(4): 324-326. doi: 10.7507/1671-6205.201612029 Copy

1.	Gold Executive Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (Revised 2013) [EB/OL]. [2013-11-20]. Available at http://goldcopd.org.
2.	荣蓉. 慢性阻塞性肺疾病急性加重期下呼吸道感染细菌特点及耐药性分析. 国际呼吸杂志, 2015, 35(15): 1149-1151.
3.	谢岚, 毛欣, 李建刚, 等. 降钙素原在慢性阻塞性肺疾病急性加重期抗生素使用中的指导意义. 中国呼吸与危重监护杂志, 2013, 12(3): 237-239.
4.	Morgenthaler NG, Mailer B, Struck J, et al. Copeptin, a stable peptide of the arginine vasopressin precursor is elevated in hemorrhagic and septic shock. Shock, 2007, 28(2): 219-226.
5.	Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest, 2007, 131(4): 1058-1067.
6.	Neuhold S, Huelamann M, Strunk G, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol, 2008, 52(4): 266-272.
7.	刘海玉, 周国平, 李东峰, 等. 血清和肽素、降钙素原及超敏 C-反应蛋白对脑出血患者肺部感染早期诊断及预后判断的价值. 中华医院感染学杂志, 2016, 26(23): 5410-5412.
8.	赵玉清, 袁桂莉, 张进顺, 等. 和肽素联合 N 末端 B 型利钠肽原评估慢性心力衰竭患者预后的价值. 中国循环杂志, 2014, 29(4): 275-278.
9.	吴鑫虎, 邱俏檬, 洪广亮, 等. 血清和肽素对脓毒症早期诊断及预后评估的临床意义. 中国急救医学, 2012, 32(7): 589-591.
10.	中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013 年修订版). 中华结核和呼吸杂志, 2013, 36(4): 255-264.
11.	慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组. 慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2014 年修订版). 国际呼吸杂志, 2014, 34(1):1-11.
12.	Mackay AJ, Hurst JR. COPD exacerbations: causes, prevention, and treatment. Immunol Allergy Clin North Am, 2013, 33(1): 95-115.
13.	Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J, 2004, 23(6): 932-946.
14.	Miller M. Hyponatremia and arginine vasopressin dysregulation: mechanisms, clinical consequences, and management. J Am Geriatr Soc, 2006, 54(2): 345-353.
15.	Jochberger S, Morgenthaler NG, Mayr VD, et al. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab, 2006, 91(11): 4381-4386.
16.	Valli G, Fedeli A, Antonucci R, et al. Water and sodium imbalance in COPD patients. Monaldi Arch Chest Dis, 2004, 61(2):112-116.
17.	Christ-Crain M, Mailer B. Biomarkers in respiratory, tract infections:diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J, 2007, 30(3): 556-573.
18.	赵云峰, 林勇, 张卫国. 社区获得性肺炎患者血清合肽素测定的临床意义. 中华结核和呼吸杂志, 2009, 32(12):911-914.
19.	Morgenthaler NG, Struck J, Alonso C, et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem, 2006, 52(1): 112-119.
20.	曾宪威. 降钙素原和 C-反应蛋白水平及白细胞计数联合检测对呼吸道感染的诊断价值. 中华实验和临床感染病杂志(电子版), 2016, 10(1): 69-72.

1. Gold Executive Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (Revised 2013) [EB/OL]. [2013-11-20]. Available at http://goldcopd.org.
2. 荣蓉. 慢性阻塞性肺疾病急性加重期下呼吸道感染细菌特点及耐药性分析. 国际呼吸杂志, 2015, 35(15): 1149-1151.
3. 谢岚, 毛欣, 李建刚, 等. 降钙素原在慢性阻塞性肺疾病急性加重期抗生素使用中的指导意义. 中国呼吸与危重监护杂志, 2013, 12(3): 237-239.
4. Morgenthaler NG, Mailer B, Struck J, et al. Copeptin, a stable peptide of the arginine vasopressin precursor is elevated in hemorrhagic and septic shock. Shock, 2007, 28(2): 219-226.
5. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest, 2007, 131(4): 1058-1067.
6. Neuhold S, Huelamann M, Strunk G, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol, 2008, 52(4): 266-272.
7. 刘海玉, 周国平, 李东峰, 等. 血清和肽素、降钙素原及超敏 C-反应蛋白对脑出血患者肺部感染早期诊断及预后判断的价值. 中华医院感染学杂志, 2016, 26(23): 5410-5412.
8. 赵玉清, 袁桂莉, 张进顺, 等. 和肽素联合 N 末端 B 型利钠肽原评估慢性心力衰竭患者预后的价值. 中国循环杂志, 2014, 29(4): 275-278.
9. 吴鑫虎, 邱俏檬, 洪广亮, 等. 血清和肽素对脓毒症早期诊断及预后评估的临床意义. 中国急救医学, 2012, 32(7): 589-591.
10. 中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013 年修订版). 中华结核和呼吸杂志, 2013, 36(4): 255-264.
11. 慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组. 慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2014 年修订版). 国际呼吸杂志, 2014, 34(1):1-11.
12. Mackay AJ, Hurst JR. COPD exacerbations: causes, prevention, and treatment. Immunol Allergy Clin North Am, 2013, 33(1): 95-115.
13. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J, 2004, 23(6): 932-946.
14. Miller M. Hyponatremia and arginine vasopressin dysregulation: mechanisms, clinical consequences, and management. J Am Geriatr Soc, 2006, 54(2): 345-353.
15. Jochberger S, Morgenthaler NG, Mayr VD, et al. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab, 2006, 91(11): 4381-4386.
16. Valli G, Fedeli A, Antonucci R, et al. Water and sodium imbalance in COPD patients. Monaldi Arch Chest Dis, 2004, 61(2):112-116.
17. Christ-Crain M, Mailer B. Biomarkers in respiratory, tract infections:diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J, 2007, 30(3): 556-573.
18. 赵云峰, 林勇, 张卫国. 社区获得性肺炎患者血清合肽素测定的临床意义. 中华结核和呼吸杂志, 2009, 32(12):911-914.
19. Morgenthaler NG, Struck J, Alonso C, et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem, 2006, 52(1): 112-119.
20. 曾宪威. 降钙素原和 C-反应蛋白水平及白细胞计数联合检测对呼吸道感染的诊断价值. 中华实验和临床感染病杂志(电子版), 2016, 10(1): 69-72.

Chinese Journal of Respiratory and Critical Care Medicine

Clinical value of plasma copeptin in acute exacerbation of chronic obstructive pulmonary disease

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content